Tag : Prostate Cancer

Clinical Research, Pharma & Healthcare Financing

Pfizer’s TALZENNA® + XTANDI® Improve Survival in Prostate Cancer

Business Wire
Pfizer Inc. (NYSE: PFE) today announced positive results from the Phase 3 TALAPRO-2 study of TALZENNA® (talazoparib), an oral poly ADP-ribose polymerase (PARP) inhibitor, in combination with...